BridgeBio posts infigratinib achondroplasia trial presentation
PUBT · 6d ago
Share
Listen to the news
- BridgeBio published results from the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia.
- Primary endpoint met: annualized height velocity increased at week 52; LS mean difference vs placebo 1.74 cm/year (95% CI 1.31-2.17); p<0.0001.
- Height z-score improved at week 52; LS mean difference vs placebo 0.32 (96% CI 0.23-0.41); p<0.0001.
- Safety profile described as well-tolerated; treatment-emergent adverse events balanced vs placebo; no treatment-related serious adverse events or discontinuations reported.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on June 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved